🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
6.44
+0.09 (1.42%)
At close: Nov 19, 2026, 4:00 PM EST
6.32
-0.12 (-1.86%)
After-hours: Nov 19, 2026, 6:04 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

The DMD program is preparing for a late-2026 FDA discussion on accelerated approval, supported by 53 treated patients and a broad functional and biological dataset. FA data are expected in Q1 2027, while resources are focused on both programs and cash runway extends into 2028.

Maury Raycroft
Biotech Analyst, Jefferies

Maury Raycroft, one of the biotech analysts at Jefferies. I would like to welcome Bo Cumbo, the CEO of Solid Biosciences. Thanks so much for joining us today, Bo.

Bo Cumbo
CEO, Solid Biosciences

Yeah. Thank you, Maury, and thank you, Jefferies, for the invitation.

Maury Raycroft
Biotech Analyst, Jefferies

We are going to do fireside chat format. Maybe for those who are new to the story, if you can give us a brief intro to Solid and what you see as the key differentiating features of your DMD and Friedreich's ataxia programs.

Bo Cumbo
CEO, Solid Biosciences

Yeah. Thank you once again. Solid Biosciences is a precision genetic medicine company. We focus on rare disease. Currently, we are in gene therapy in two indications, primary indications, which is Duchenne muscular dystrophy, as well as Friedreich's ataxia. Both products are in the clinic. Our first program for DMD is we have dosed 53 patients. We are getting ready to meet with the FDA this quarter to talk about accelerated approval pathway, and we have started a phase III. Our second program is for Friedreich's ataxia. We have dosed five patients with multiple other patients that are scheduled to be dosed this year. We are going to meet with the FDA somewhere right around Q1, Q2 to talk about a double-blind placebo control trial, registrational trial for that program as well. Really, the differentiating factor is the delivery. One is using a muscle-specific capsid that detargets the liver.

The other is using, for Friedreich's ataxia, it's using a dual route of administration with an MRI-guided technology going right to the dentate nucleus. Both programs, we are trying to realize the importance of delivery. One is being used systemically. The other is not only systemically, but also using technology to get to the heart of the matter, which is the dentate nucleus for Friedreich's ataxia.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Yeah, it's a good introduction. You mentioned the FDA meeting coming up here in late fourth quarter. Maybe talk about your preliminary dataset. You've described a range of potential outcomes from that meeting where FDA could request additional data to supporting a path toward filing. What are the key drivers that will determine outcomes from this meeting, and will it be based on maturity and consistency of the functional data, relationship between expression and function, number of patients, or something else?

Bo Cumbo
CEO, Solid Biosciences

Well, the answer's probably yes. It's going to be a whole host of things. As I mentioned before, we've dosed 53 patients over the course of about a year and a half or so. We have 53 patients' worth of safety data that we're going to be going in with. We also have about 12 or slightly more patients that have at least one year of functional data. Not going to discuss the data that we're going to present. We're going to present that to the FDA first, and then we're going to present it to all the investors as well as all the patients after we get the minutes back from the FDA. But we're going to go in with a, I think, a very comprehensive dataset. We've been doing this from day one, looking at all the biological correlates that I think everybody knows.

You've seen it in our decks, whether it's expression to CK, to titin, to looking at troponin and ejection fraction. So we'll have all this data. We've added in additional data points to round out our biological correlate data that no one else has seen yet. We're going to present that, and then we're going to look at functional data as well. Functional data consists of time to rise, 10 m run/walk, NSAA, all the things that you would expect in Duchenne. But we also supplement this with a stride velocity 95th centile that moves away from human error or bias or coaching to help augment the data package. We'll present it to the FDA, hopefully have a very good and productive conversation, talk about next steps for accelerated approval, and then I'll notify the street of that outcome.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. If FDA is directionally supportive of accelerated approval but wants more evidence, you have already got substantially more patient data maturing behind the initial package. What is your strategy to work with the FDA, and what are the most likely rate-limiting steps at this point? Will you have to wait for additional follow-up, or potentially demonstrate something on confirmatory study enrollment?

Bo Cumbo
CEO, Solid Biosciences

It is a great question. So one of the scenarios, the FDA, to your point, there is really three scenarios, right? There is one that says, "Okay, you have got enough data. Let us go," and you start filing. Second pathway could be, okay, to your point, to your question, just need more data because I am going in with about 12, slightly more, of one year worth of data, patients with one year of data. Third could be, you have no path, finish phase III. I do not believe that that is going to be the case because I do think that this is a, and the FDA has stated itself, Duchenne is a high unmet need. Clearly, we have not solved the Duchenne problem, and these patients need choice and better therapies.

So in your middle question here, what if they say, "You need more patient data?" Well, that is, I guess, in a really positive scenario for us because as I mentioned, we dosed 53 patients. We were actually, because of the safety, being so transparent about safety, you can actually go back and look at all our presentations over time and figure out exactly how many patients we have dosed and when. In January of 2026, this year, I think we had a press release right before the conference in San Francisco, and we announced that we had dosed roughly 30 patients at that time. So that means by the end of this year, we are going to have roughly 30 patients' worth of one-year data.

When you create these briefing books and data packages for the FDA, you really have to cut off the data about five months, six months ahead of the meeting, just so you can put together the package and put together the dossier and send it in. If we hold this meeting in the next, I said we will hold this meeting this year, so that means it is coming up in the next six weeks, and we probably are not going to do it over Christmas. Then that means that I will have 30 patients' worth of data. We just do a new data cut, schedule a new meeting, provide the data, and have the meeting and have the discussion. So I think we are sitting in a really good scenario as a company, or good position as a company, in scenario one and two.

Obviously, let's hope that scenario three is not an option. I do not think it will be because these kids need something, the physicians need something, and it is still a high unmet need. I think we have a great program.

Maury Raycroft
Biotech Analyst, Jefferies

Makes sense. Your confirmatory phase III is progressing in parallel. What are key details you can share on where the status of the study will be when you have the Type C meeting, and how quickly do you think the study could reach a meaningful enrollment threshold? In your mind, what is meaningful?

Bo Cumbo
CEO, Solid Biosciences

Yeah. We have not discussed, we are not going to discuss how many patients we are dosing until we are fully enrolled. But what I have said publicly is that we really need to get Europe and some of the sites in the United States up and running, and that will happen late this quarter to early next quarter. What we currently have right now, we only have two countries, which is Canada and Australia. Enrollment is relatively slow because it is two countries. In the near future, we will have Spain, Italy, the U.K., Netherlands, France, as well as multiple sites in the United States. At that point, enrollment should speed up pretty dramatically, especially ex-U.S. and Europe, because there is just no other program available. That is progressing nicely. We do expect those sites, those countries, and those sites to open up in the next quarter.

At that point, things really ramp up. To your question about how long it takes, other public statements I said is once Europe opens up, it will be about 18 months to fully enroll that trial. Hopefully, we can do it faster, but I want to set expectations that it is an 18-month full enrollment.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. Assuming the FDA interaction is constructive, what are the major work streams that Solid Biosciences will need to advance toward a potential BLA filing?

Bo Cumbo
CEO, Solid Biosciences

Well, we're through with our PPQs. That was a big deal. The runs are done. We're doing the analysis right now and then putting them in vial and all that. PPQs are complete, and we'll have to do the runs. Obviously, make the modules, start the modules. CMC will be last, and we've publicly stated in the past, if everything goes smoothly, if we have a great meeting and they just say, "You know what? This is good enough," then we could be looking at completing the filing by mid-year of next year.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. FDA is going to see patient-level functional data across different measures together with expression function analyses. You've highlighted some of the functional measures that are important. Study's open label, so what would give you the greatest confidence that the functional signal represents a true treatment effect, and how do you weigh different variables like durability within individual patients and consistency?

Bo Cumbo
CEO, Solid Biosciences

So, one of the conversations that we had with the FDA in the March timeframe, in the second meeting. We've actually had, by the way, in the last 12 months, three meetings with the FDA on this program. So, they're very aware of the program, and we've had very meaningful conversations with them, first with the phase III, second with sort of the data expression discussion as well as safety, and then they gave us some guidance on what they wanted to see. What they want to see is they want to see directional correlation, directional clinical benefit tied back to microdystrophin. That's what we intend to provide them. We're looking at a whole host of measures, time to rise, 10 m run/walk, NSAA.

But one of the statements that the FDA has said to us is one of the issues that they worry about, one of the things they worry about in open-label studies is the ability for bias, coaching, human error. And obviously, it is right for them to think that way in an open-label study. So what we did was, to your question, what gives us confidence is like you also augment those clinical endpoints with stride velocity 95th centile that does not have any human intervention. So for those of you who don't know what stride velocity 95th centile is, you put little ankle monitors on the child. They have to wear it four weeks ahead of time coming into each visit. So baseline visit, three-month visit, six-month visit, nine-month visit. They have to wear these little ankle monitors for four weeks ahead of time.

They have to gather at least 50 hours of data to 150 hours of data, and it is analyzed without a human intervention. Humans don't look at it. It is all digital. And then this gives you. And you strip away 95% of the movement. You are only looking at the top 5% of their daily values, and you obviously have a baseline. This gives you good data that humans can't touch, humans can't intervene. There is no way to coach. And hopefully what you see is you see stride velocity pointing in the same direction that other measures will be pointing, time to rise, 10 m run/walk. That is going to give you a lot of confidence that the data set is real.

So, when you are looking at your primary endpoint in our phase III is time to rise, if you see something positive and you also see something positive in stride velocity, it gives you a lot of confidence. And then you have, I don't know how many measures, I think it was about 11 different biological correlate measure. It is the most comprehensive data set I think that any company has put together in Duchenne. Hopefully, we have good data for the FDA to discuss, and then we are going to share that with all the investors immediately after we get the meeting minutes. So, I think that is important. I won't have the meeting and just go out there. I will wait for the meeting minutes, and then we will share it with you.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. And as far as durability for individual patients goes, is that something that FDA has commented on and—

Bo Cumbo
CEO, Solid Biosciences

They've never commented to us about that. I believe durability. I actually believe this Sarepta data gives you confidence that durability exists in microdystrophins. I believe in microdystrophins. I believe they are beneficial. I think every program's unique and different depending on the proteins that you're recruiting for and the amount of microdystrophin you can recruit for the child. But durability, obviously, we've only got a handful of patients that are out 18 months. Maybe they'll ask in the meeting. They have not done so as of today.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. As far as the functional measures correlating with each other, have you looked at that yet, or you're still?

Bo Cumbo
CEO, Solid Biosciences

We're still processing it. We're still analyzing it, but we've obviously submitted the briefing book because the meeting is held this year.

Maury Raycroft
Biotech Analyst, Jefferies

Right. Okay. You'll also have analyses relating the microdystrophin expression to subsequent function. How important do you think a patient-level expression- function relationship will be to your overall accelerated approval argument, and what type of relationship would you view as biologically convincing?

Bo Cumbo
CEO, Solid Biosciences

Well, they want to see directional clinical benefit, and we're going to provide them all the data. We're going to provide them all the data by individual patients for expression and individual patients for time to rise, in NSAA, four-stair climb. They can do their own analysis. We're going to do our analysis. I'm sure they'll do theirs. There's a lot of data there. I think there's a lot of biological correlate data, there's a lot of functional data, and they're going to be able to assess this. We're just going to have to have the meeting and discuss it.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Right. As the public data set expands beyond the initial FDA package, is it more about replicating the observations in more patients, or are there other?

Bo Cumbo
CEO, Solid Biosciences

Yeah. No, no, I think that's it. You want to continue to see safety. I think you want to continue to see directional clinical benefit. You want to continue to see microdystrophin expression and the biological correlate data track from day 98 to day 360, because that'll be our last biopsy, day 360. If you can do that, the totality of the data should be enough. Safety's critically important in this disease. I think we've dosed 53 patients all the way down to six months of age. Six months was our lowest, youngest child. 10 years of age was our oldest child. We've never had drug-induced liver injury. We've never had myocarditis. We've never had TMA/aHUS. We've learned a lot about this capsid. It clears out of the blood in four days in our patients.

The biological correlate data has stayed down, as you can see in the last presentation that I gave publicly. I did show updated biological data. We only use steroids. We don't use enhanced immune reduction, so we don't use sirolimus, we don't use eculizumab. Our steroid regimen's only 30 days. It's outpatient dosing. I think all of this matters to the community, to the KOLs, hopefully to the FDA, and we're just going to have to have that discussion.

Maury Raycroft
Biotech Analyst, Jefferies

Makes sense. With the space evolving, with some of the other competitors out there, you've emphasized SGT-003's next-gen capsid, the muscle targeting and safety profile. What do you ultimately need to show on efficacy and safety for you to consider it meaningfully differentiated from the other approaches?

Bo Cumbo
CEO, Solid Biosciences

From a safety standpoint, I think I'm already there. I just rattled off what we don't have, and no one else can say that. The other companies are having to use an enhanced immune suppression regimen. We don't have to do that. From a safety standpoint, with dosing 53 patients, including the youngest Duchenne patient that's ever been dosed, with using steroids only and not seeing liver injury, myocarditis, TMA/aHUS, I think that speaks on its own. Hopefully the FDA sees that. From an efficacy standpoint, I think the other companies have also shown that they have directional clinical benefit, and hopefully we can show that to the FDA as well. Then we'll just have to work with the FDA on a path forward.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. One of the competitors, REGENX, is right ahead of you from a regulatory timing perspective. What, if anything, are you learning from seeing another investigational Duchenne gene therapy program move through the regulatory process?

Bo Cumbo
CEO, Solid Biosciences

It gives me confidence. I had confidence many years ago that microdystrophins work. You can see it in the animal studies. I do believe that there is a threshold in these children, a little bit different than the golden retrievers or the mice, but there is something there. REGENX data had positive data. I think the long-term Sarepta data had positive data. I think Sarepta has safety issues. This opens us up for a good opportunity there. We'll just, like I said, I think have to have the discussion, but I'm pretty positive about everything.

Maury Raycroft
Biotech Analyst, Jefferies

How closely do you think FDA will benchmark you versus REGENX, and will there be consistency with how FDA treats you both, given the similar approaches?

Bo Cumbo
CEO, Solid Biosciences

I've been in the industry a very long time, 32, 33 years. I've launched a lot of drugs. In those couple of my launches, one with INCIVEK for hepatitis C when we were competing against Merck. The other one was in Duchenne at Sarepta when we were launching EXONDYS, but at that time competing against Prosensa and BioMarin. The FDA found a way to bring both programs closer together so they could review things in tandem, especially important diseases like this. This is my personal opinion, is that they're not going to treat one company different than the other. I think that would be a bad signal for the FDA, for the community, for the KOLs. I think it's going to be very fair and opinionated and hopefully merge the two together and review the two in parallel.

I think REGENX has said that they would file Q1. You just asked me on stage if everything goes well, when would we file? I said midsummer. It wouldn't surprise me to see the two sort of have parallel paths, because I've seen that in the past in my career, both with hepatitis C as well as DMD with the first-gen exon-skipping drugs.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. That makes sense. Let's shift gears and talk about Friedreich's ataxia in the last couple of minutes. You disclosed that five patients had been dosed at your third quarter update with a more fulsome initial data set expected first quarter of 2027. What do you aim to show in the initial data?

Bo Cumbo
CEO, Solid Biosciences

Number one, safety. We are dealing with the most severe patient population in FA, and that was a choice, our choice, our decision to go into these patients. Our mFARS is 70 and 80. They are the most severe of all the FA patients. Many of them are strapped in. They have no upper limb function, no lower limb function, really severe hearts, cannot speak, cannot swallow, cannot read. Safety is number one. Second, if we start seeing any of these benefits, especially in the first three patients, because we will have longer data set. We have dosed patient four and five relatively recently, so we should have at least 90 days' worth of data looking at mFARS or modified mFARS and also any changes in speech or at least anecdotal data from there. Then that is going to be beneficial. These patients do not get better.

One thing about mFARS is it always climbs up, and that is not good. They never stall out. They just continue to progress. Depending on where the patient starts determines how many points you lose in a year. The patients that we are dealing with, high mFARS, patients 70, 80, et cetera, you can always expect a point a year to 0.5 point a year. If we can halt the disease, I know some investors do not believe that a halt is meaningful. I would say that for FA, a halt is meaningful, especially when you are at the end of life and you are grasping onto anything. But if you can decline mFARS, then it is pretty dramatic. That means you have gained function back. You typically do not see gain of function back.

Put it in perspective, if you are at mFARS 80 and you lose 0.5 point a year or gain 0.5 point a year or gain a point a year, and you can show 0.5 point reduction, you really brought them back a year or two and brought back some function. That is going to be massively important to this community. We are the only drug that I know of that is going right to the dentate nucleus, right to the source of the matter of the neurological manifestations of the disease. We think it is critically important. You have to cover the dentate nucleus at least 15%-20%. You cannot do that with a neurotrophic drug. You cannot do that with an IV drug. We think this is going to matter.

I think if the community sees benefit, they are going to gravitate to this drug. We are just going to have to wait. The data will be released almost on top of Duchenne, so you might get a one-two punch. The FA market, because of the patient population, because of the severity, it is as big, if not bigger, from a commercial process, especially in Europe, ironically. Europe has a lot more patients than the U.S. in FA, and we intend to keep both drugs. We own both. We have never put any rights out there, and I want to commercialize both the Duchenne and FA programs ourself at Solid, and turn this into a multi-billion- dollar company in the next couple years.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Makes sense. You mentioned data first quarter of next year, then FDA meeting in second quarter, then potentially talk about a pivotal study.

Bo Cumbo
CEO, Solid Biosciences

Absolutely. We are going to go in for a double-blind placebo control trial in FA. Dr. Brooks, who is in the audience, and myself, we have already talked to FARA about this. We think it is critically important so I can get reimbursement for the tens of thousands of patients in Europe, and get reimbursed. We are going to do a double-blind placebo control trial. If we see something in Q1, that is going to give us a lot of confidence that we can hit a P value if we develop the trial correct. We are going to commercialize this in Europe and U.S., and there is tens of billions of dollars of opportunity, not just in the U.S., but also in Europe with this drug.

Maury Raycroft
Biotech Analyst, Jefferies

Is there confidence around the FDA meeting and starting that controlled study? Is that based on what you are seeing currently, or is it primarily just proactive?

Bo Cumbo
CEO, Solid Biosciences

Mainly, we do not have all the data together on the mFARS, but anecdotal data, comments from the physicians, the PIs, and the families, we are hearing a lot. Yeah.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. As far as I think we're almost out of time, but as you gain confidence in SGT-003's regulatory and approval path, how does that change the way you allocate resources across SGT-212 and the earlier stage pipeline?

Bo Cumbo
CEO, Solid Biosciences

We already have. As you know, we had a third program called CPVT. We've slowed it down dramatically. We also had another program called TNNT2 for dilated cardiomyopathy. It's ready for the IND filing. We didn't put that in because we're putting all our resources to the biggest inflection points for investors, and that's going to be a one-two punch of DMD, FA. We're 156 employees. Every person is now focused on these two, because I think that can be a one-two punch within approval, within very short time of each other, and these are going to be tens of billions of dollars in both disease states, and we own the global rights. So all our efforts on one and two.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay, so in closing, maybe just highlight your cash and runway, and just how investors should think about key catalysts ahead.

Bo Cumbo
CEO, Solid Biosciences

$350 million as end of Q3, and that takes us into 2028.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay, thanks so much for joining us today, Bo.

Bo Cumbo
CEO, Solid Biosciences

Thank you.